<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076110</url>
  </required_header>
  <id_info>
    <org_study_id>21-003441</org_study_id>
    <nct_id>NCT05076110</nct_id>
  </id_info>
  <brief_title>Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures</brief_title>
  <official_title>Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the effectiveness of post-operative pain control&#xD;
      without using narcotic pain medications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pain score</measure>
    <time_frame>Baseline, 14 days post-operatively</time_frame>
    <description>Measure using a visual analog scale (VAS) to rate pain on a scale 0-10; 0=no pain to 10=worst possible pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Hip Arthroscopy</condition>
  <arm_group>
    <arm_group_label>Standard of Care Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive standard of care pain medication Oxycodone for pain control following hip arthroscopy procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Opiate Pain Control Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a non-opiate pain control regime using Ibuprofen, Gabapentin, Acetaminophen, Methocarbamol for pain control following hip arthroscopy procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone</intervention_name>
    <description>5 mg tablets every 4 hours postoperatively as needed for pain control</description>
    <arm_group_label>Standard of Care Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>800 mg three times a day for 2 weeks postoperatively for pain control; not to exceed 3200 mg/day</description>
    <arm_group_label>Non-Opiate Pain Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>300 mg three times a day for 5 days then wean off by day 10 postoperatively</description>
    <arm_group_label>Non-Opiate Pain Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen</intervention_name>
    <description>1000 mg three times a day for up to 4 weeks postoperatively for pain control; not to exceed 4 grams per day</description>
    <arm_group_label>Non-Opiate Pain Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methocarbamol</intervention_name>
    <description>500 mg three times a week for 2 weeks postoperatively</description>
    <arm_group_label>Non-Opiate Pain Control Group</arm_group_label>
    <other_name>Robaxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢ Scheduled for a primary Hip Arthroscopy at Mayo Clinic (Rochester, MN)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical history of known allergies or intolerance to allergies or intolerance to&#xD;
             Motrin, Gabapentin, Tylenol, dexamethasone, tramadol, or Robaxin.&#xD;
&#xD;
          -  Substantial alcohol or drug abuse.&#xD;
&#xD;
          -  History of narcotics within 6 months of surgery.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Renal impairment.&#xD;
&#xD;
          -  Peptic ulcer disease.&#xD;
&#xD;
          -  GI bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelechi Okoroha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Kelechi R. Okoroha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Gabapentin</mesh_term>
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

